Angiogenesis and tumour proliferation in hepatocellular carcinoma after trans-arterial therapy

Effect of trans-arterial chemo embolization therapy on angiogenesis and tumour proliferation in patients with hepatocellular carcinoma

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

SLCTR

Registry ID

SLCTR/2016/023

Enrollment

Unknown

Registered

2016-09-28

Start date

2016-09-28

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

Patients presenting to the North Colombo Teaching Hospital and have resectable small (smaller than 5cm) HCC will be randomly allocated into 2 groups. Based on patients’ liver functions and the contr

Eligibility

Inclusion criteria

Inclusion criteria: Patients diagnosed with resectable hepatocellular carcinoma (tumour less than 5cm as determined by contrast enhanced CT scan) indicated for surgery

Exclusion criteria

Exclusion criteria: 1. Portal vein and hepatic vein invasion needing urgent intervention 2. Allergy to contrast material or doxorubicin

Design outcomes

Primary

Measure	Time frame
1. Degree of cell necrosis The specimen will be stained with haematoxylin and eosin. Each zone will be assessed by two different pathologists experienced in reporting liver specimens. The degree of cell death will be examined under the light microscope. The absolute degree of cell death will be given as a percentage figure after examining 10 high power fields. When there is more than 5% difference between the pathologists the slides will be re-evaluated and a common figure will be agreed upon on the degree of cell death. The degree of cell death will be documented in each intra tumour zones and peritumour zones. 2. Tumour proliferative index After the staining with KI 67 the specimens will be examined under the light microscope. 10 high power fields will be examined. The percentage of KI 67 positive cells will be documented as proliferative index. [The specimen will be fixed and sent for pathological evaluation immediately following surgical resection]	—

Measure

Time frame

1. Degree of cell necrosis The specimen will be stained with haematoxylin and eosin. Each zone will be assessed by two different pathologists experienced in reporting liver specimens. The degree of cell death will be examined under the light microscope. The absolute degree of cell death will be given as a percentage figure after examining 10 high power fields. When there is more than 5% difference between the pathologists the slides will be re-evaluated and a common figure will be agreed upon on the degree of cell death. The degree of cell death will be documented in each intra tumour zones and peritumour zones. 2. Tumour proliferative index After the staining with KI 67 the specimens will be examined under the light microscope. 10 high power fields will be examined. The percentage of KI 67 positive cells will be documented as proliferative index. [The specimen will be fixed and sent for pathological evaluation immediately following surgical resection]

—

Secondary

Measure	Time frame
Degree of Vascular Endothelial Growth Factor (VEGF) expression in each tumour zone as a surrogate marker for tumour angiogenesis. [At baseline and 6 weeks following TACE]	—

Countries

Sri Lanka

Contacts

Public ContactDr. Rohan C Siriwardana

Consultant Hepatobiliary Surgeon

rohansiriwardana@yahoo.comTel: 0775544015

Outcome results

None listed

Source: SLCTR (via WHO ICTRP) · Data processed: Aug 9, 2026